Group 1 - The core point of the article is that Medike announced a plan for a major shareholder, Fengshengjiamei, to reduce its stake in the company by up to 4,109,297 shares, which represents no more than 1.00% of the total share capital, during the period from February 2, 2026, to May 1, 2026 [1] Group 2 - The shares to be reduced were acquired before the company's IPO [1]

证券代码：688079 证券简称：美迪凯 公告编号：2026-002 杭州美迪凯光电科技股份有限公司 减持计划的主要内容 减持主体计划自本公告披露之日起 15 个交易日后即 2026 年 2 月 2 日起的 3 个月内，减持股份不超过 4,109,297 股，即不超过总股本的 1.00%，均通过集中 竞价方式减持，减持价格按市场价格确定。在有关法律法规、规范性文件规定的 不得减持期间内不减持股份。若在减持计划期间公司有送股、配股等股份变动事 项，减持股份数量相应调整；若公司有可转换公司债券转股、股权激励增发新股、 非公开发行股票等引起的股份变动事项，减持股份数量不做调整。 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 杭州美迪凯光电科技股份有限公司（以下简称"公司"）股东香港豐盛佳美 （國際）投資有限公司（以下简称"丰盛佳美"、"减持主体"）持有公司股份 20,688,792股，占公司总股本的5.0346%。上述股份来源为公司IPO前取 ...

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]

格隆汇1月11日丨美迪凯(688079.SH)公布，股东丰盛佳美计划自本公告披露之日起15个交易日后即2026 年2月2日起的3个月内，减持股份不超过4,109,297股，即不超过总股本的1.00%，均通过集中竞价方式 减持，减持价格按市场价格确定。在有关法律法规、规范性文件规定的不得减持期间内不减持股份。若 在减持计划期间公司有送股、配股等股份变动事项，减持股份数量相应调整；若公司有可转换公司债券 转股、股权激励增发新股、非公开发行股票等引起的股份变动事项，减持股份数量不做调整。 ...

格隆汇1月11日丨美迪凯(688079.SH)公布，股东丰盛佳美计划自本公告披露之日起15个交易日后即2026 年2月2日起的3个月内，减持股份不超过4,109,297股，即不超过总股本的1.00%，均通过集中竞价方式 减持，减持价格按市场价格确定。在有关法律法规、规范性文件规定的不得减持期间内不减持股份。若 在减持计划期间公司有送股、配股等股份变动事项，减持股份数量相应调整；若公司有可转换公司债券 转股、股权激励增发新股、非公开发行股票等引起的股份变动事项，减持股份数量不做调整。 ...

智通财经APP讯，美迪凯(688079.SH)发布公告，公司股东香港豐盛佳美(國際)投資有限公司(简称"丰盛 佳美")计划自公告披露之日起15个交易日后即2026年2月2日起的3个月内，减持股份不超过410.93万 股，即不超过总股本的1%。 ...

人民财讯1月11日电，美迪凯(688079)1月11日公告，持股5.0346%的股东香港豐盛佳美(國際)投資有限公 司计划减持股份不超过410.93万股，即不超过总股本的1%，均通过集中竞价方式减持，减持价格按市 场价格确定。 ...

美迪凯公告称，股东香港豐盛佳美（國際）投資有限公司持有公司股份20,688,792股，占总股本的 5.0346%，股份已于2022年3月2日解禁流通。该股东计划自2026年2月2日起3个月内，通过集中竞价减 持不超4,109,297股，即不超总股本的1%，减持价格按市场价定。过去12个月内，其已减持12,201,499 股，比例为3%。本次减持因自身资金需求，实施存在不确定性。 ...

Core Viewpoint - The announcement details the implementation and results of the 2024 stock option and restricted stock incentive plan of Hangzhou Medike Technology Co., Ltd, highlighting the number of options exercised and the stock's circulation arrangements. Group 1: Stock Option Exercise Details - The first exercise period for the stock options under the 2024 incentive plan allows for the exercise of 3,506,280 options, with an actual exercise period from November 21, 2025, to November 17, 2026, and 2,270,926 shares have been exercised by December 31, 2025, accounting for 64.77% of the available options [2][10] - The stock acquired through the exercise will be credited to the accounts of the incentive participants on the first trading day after the exercise date (T+1) and will be available for trading on the second trading day (T+2) [3] Group 2: Approval and Implementation of the Incentive Plan - The stock option incentive plan was approved during the board meeting on September 27, 2024, and subsequently, the plan was publicly announced and no objections were raised during the internal disclosure period [4][5] - The number of incentive recipients was adjusted from 428 to 343, and the total number of stock options granted was reduced from 9,632,000 to 8,827,700 [6] Group 3: Changes in Shareholding and Financial Impact - The exercise of stock options resulted in an increase in total shares, leading to a dilution of the shareholding percentage of the controlling shareholder and its concerted parties [16] - The funds raised from the exercise, amounting to 16,736,724.62 yuan, will be used to supplement the company's working capital [16] - The exercise of options is not expected to have a significant impact on the company's financial status or operating results [17]

证券代码：688079 证券简称：美迪凯 公告编号：2026-001 杭州美迪凯光电科技股份有限公司 关于2024年股票期权与限制性股票激励计划2025年第四 季度自主行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次行权数量： 杭州美迪凯光电科技股份有限公司（以下简称"公司"）2024年股票期权 与限制性股票激励计划（以下简称"本激励计划"）首次授予股票期权第一个 行权期可行权数量为3,506,280份，实际可行权期为2025年11月21日至2026年11 月17日（行权日须为交易日），行权方式为自主行权。2025年11月21日至2025 年12月31日期间，累计行权并完成股份过户登记数量为2,270,926股。截至2025 年12月31日，累计行权并完成股份过户登记数量2,270,926股，占本期可行权额 度3,506,280股的64.77%。 本次行权股票上市流通时间： 一、股权激励计划批准及实施情况 4、2024年11月18日公司第二届董事会第二十次会议审议通过《关于调整 ...